The SPARC-1 pilot study (NCT04028245) is currently recruiting localized ccRCC patients to evaluate the combination of canakinumab (ACZ885, IL-1β inhibitor) and spartalizumab (PDR001, PD-1 inhibitor) prior to radical nephrectomy. This evidence concerns the gene IL1B and nonpapillary renal cell carcinoma.